Adverse events of the co-packaged medication, regardless of causality, observed in the phase II-III EPIC-HR study included dysgeusia (4.8%–6%), diarrhea (3%–3.9%), vomiting (1.3%), hypertension (1%), and myalgia (1%).
Nirmatrelvir/ritonavir
Atazanavir/ritonavir
Atazanavir/cobicistat
Darunavir/cobicistat
Cabotegravir/rilpivirine
Ombitasvir/paritaprevir/ritonavir
Abacavir/lamivudine
Dolutegravir/rilpivirine